Natural Killer Cells Therapeutics Market By Type (NK Cell Therapies and Antibody Directed NK Cell Therapies); By Therapeutic Indication (Cancer, Viral Infections, Autoimmune Diseases, Neurodegenerative Diseases, and Others); By Source (Peripheral Blood, Umbilical Cord Blood, Induced Pluripotent Natural killer cells therapeutics (iPSC), and Others); By End User (Hospitals & Clinics, Research Institutes, and Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America); – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 - 2029
Industry Trends
Natural Killer (NK) cells are lymphocytes in the same family of cells from which T cells and B cells hail. As cells of the innate immune system, NK cells are classified as group I Innate Lymphocytes (ILCs). Able to respond quickly to a wide variety of pathological challenges, NK cells can kill virally infected cells. They can also detect as well as control early signs of cancer. Many factors are driving the global natural killer cells therapeutics market but the most important factor is growing prevalence of cancer. Interferon γ (IFN-γ) aids in cancer elimination by inhibiting angiogenesis cellular proliferation. It promotes apoptosis, and stimulates the adaptive immune system. It is also instrumental for enhancing antigen (Ag) processing and Ag presentation. However, the lack of specificity and poor in-vivo survival of the cells limits the growth of global natural killer cells therapeutics market.
With the sudden emergence of respiratory viruses such as SARS-CoV-2, also known as coronavirus or COVID-19, many people have died and many are hospitalized in critical condition. SARS stands for Severe Acute Respiratory Syndrome. In order to develop an effective cure and treatment, experiments with therapeutics are being carried out. Moreover, many scientists also experimented with different antibodies. At some medical research centres, experiments were carried out using NK cells to exacerbate lung damage caused by coronavirus. The results of experiments conducted on mice were declared positive, which indicates positive growth trajectory for global natural killer cells therapeutics market over the future years.
The attempts to manipulate NK cells for utilization in the immunotherapy of cancer showcases significant growth opportunities for global natural killer cells therapeutics market over the forecast period. NK cells are most effective cells toward cancer in innate immunity. They are highly heterogeneous in the microenvironment. Most of the current treatment options that use NK cells focus on T cell-immunity to harness the tumor microenvironment. They do that either by promoting activating signals or by suppressing inhibitory ones.
Absolute Market Insights reports, the global natural killer cells therapeutics market is likely to grow at 17% CAGR during the 2021-2029 period, and reach a valuation of US$ 6317.20 Mn by 2029.
Global Natural Killer Cells Therapeutics Market Revenue & Forecast, (US$ Million), 2015 – 2029
Type Outlook:
On the basis of types, the global natural killer cells therapeutics market covers NK cell therapies and antibody directed NK cell therapies. In 2020, the NK cell therapies held the larger market share.
During the forecast period, the antibody directed NK cell therapies category is estimated to grow at the fastest rate. In this medical procedure, NK cells can kill cancer cells through antibody-dependent cellular cytotoxicity (ADCC), preventing the further spread of cancer. The binding of the fragment crystallizable (Fc) of Immunoglobulin G (IgG) to the Fcγ receptor III (FcγRIIIa/CD16a) on NK cells can create a bridge between the NK cell and the tumor cell. It also leads to tumor lysis that is mediated by NK cells. Therapeutic efficacy for anti-tumor monoclonal antibodies can increase due to this. NK cells can produce a wide variety of cytokines and chemokines that include granulocyte-colony stimulating factor (G-CSF), IFNγ, Tumor necrosis factor alpha (TNFα), Transforming growth factor beta (TGF-β), macrophage inflammatory protein 1-beta (MIP-1β), and RANTES (Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted)
Therapeutic Indication Outlook:
The therapeutic indication segment in the global natural killer cells therapeutics market has been broadly segmented into cancer, viral infections, autoimmune diseases, neurodegenerative diseases, and others. Viral infections’ therapeutic indication segment in the global natural killer cells therapeutics market is anticipated to escalate at the highest rate over the forecast period. NK cells are essential in the early immune response against viral infections and are commonly used for clearing virus-infected cells. In modern times, viruses have evolved and they can evade many medical tests that are conducted to determine what kind of virus is infecting the patient. Many unrelated viruses, including human immunodeficiency virus, influenza virus, and respiratory syncytial virus can directly interfere with the functioning of NK cells through infection. However, NK cells have various mechanisms to kill virus-infected cells, such as engaging the extracellular death receptors and exocytosis of cytolytic granules. NK cells mediate cytolysis through engagement of death receptors expressed on target cells. They mediate by expressing multiple extracellular ligands, such as Fas ligand (FasL) and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Source Outlook:
On the basis of source, the global natural killer cells therapeutics market is classified into peripheral blood, umbilical cord blood, induced pluripotent natural killer cells therapeutics (iPSC), and others. In 2020, the peripheral blood segment held the larger market share.
During the forecast period, induced pluripotent stem cell (iPSC) category is estimated to register highest growth rate. iPSC are defined as stem cells derived from normal cells such as skin cells. They are used for generating NK cells. iPSC product platform enables mass production of many engineered homogeneous cell products that help doctors to deliver more effective pharmacologic activity by administering with multiple doses. With right combination, many other cancer treatments become possible due to this. iPSCs from human cells possess the two unique properties. These properties are unlimited self-renewal and differentiation potential into all cell types of the body.
Region Outlook:
In 2020, North America dominated the global natural killer cells therapeutics market. The significant investments towards research and developments along with presence of established market participants in the region is contributing towards the region’s growth in the global market. During the forecast period, Asia Pacific region is estimated to register highest growth rate due to increasing healthcare expenditure and increasing budgetary allocations by governments in Asian countries towards development of healthcare infrastructure.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of natural killer cells therapeutics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global natural killer cells therapeutics market are Acepodia Inc., Affimed GmbH, Artiva Biotherapeutics Inc., Bellicum Phamaceuticals Inc., Cytovia Therapeutics, Dragonfly Therapeutics, EMERCell, Fate Therapeutics, Fortress Biotech Inc., Glycostem, ImmunityBio Inc., Innate Pharma S.A., Kiadis Pharma, Nkarta Inc., NKGen Biotech, NKMAX Co. Ltd., and ONK Therapeutics Limited amongst others.
Global Natural Killer Cells Therapeutics Market:
By Type
- NK Cell Therapies
- Antibody Directed NK Cell Therapies
By Therapeutic Indication
- Cancer
- Viral Infections
- Autoimmune Diseases
- Neurodegenerative Diseases
- Others
By Source
- Peripheral Blood
- Umbilical Cord Blood
- Induced Pluripotent Natural killer cells therapeutics (iPSC)
- Others
By End Users
- Hospitals & Clinics
- Research Institutes
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Natural Killer Cells Therapeutics Market
6. Market Synopsis:
Natural Killer Cells Therapeutics Market
7. Natural Killer Cells Therapeutics Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Natural Killer Cells Therapeutics Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Natural Killer Cells Therapeutics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Natural Killer Cells Therapeutics Market
8. Global Natural Killer Cells Therapeutics Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
8.2. Global
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Type
8.2.1. NK Cell
Therapies
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2020
8.2.1.3. Market Forecast, 2021 – 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 – 2020
8.2.1.5.1.2. Market
Forecast, 2021 – 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2020
8.2.1.5.2.2. Market
Forecast, 2021 – 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2020
8.2.1.5.3.2. Market
Forecast, 2021 – 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2020
8.2.1.5.4.2. Market
Forecast, 2021 – 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 – 2020
8.2.1.5.5.2. Market
Forecast, 2021 – 2029
8.2.2. Antibody
Directed NK Cell Therapies
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2020
8.2.2.3. Market Forecast, 2021 – 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 – 2020
8.2.2.5.1.2. Market
Forecast, 2021 – 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2020
8.2.2.5.2.2. Market
Forecast, 2021 – 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2020
8.2.2.5.3.2. Market
Forecast, 2021 – 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2020
8.2.2.5.4.2. Market
Forecast, 2021 – 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 – 2020
8.2.2.5.5.2. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Natural Killer Cells Therapeutics Market Analysis and
Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
9.2.1. Cancer
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 – 2020
9.2.1.3. Market Forecast, 2021 – 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 – 2020
9.2.1.5.1.2. Market
Forecast, 2021 – 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2020
9.2.1.5.2.2. Market
Forecast, 2021 – 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2020
9.2.1.5.3.2. Market
Forecast, 2021 – 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2020
9.2.1.5.4.2. Market
Forecast, 2021 – 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 – 2020
9.2.1.5.5.2. Market
Forecast, 2021 – 2029
9.2.2. Viral
Infections
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 – 2020
9.2.2.3. Market Forecast, 2021 – 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 – 2020
9.2.2.5.1.2. Market
Forecast, 2021 – 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2020
9.2.2.5.2.2. Market
Forecast, 2021 – 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2020
9.2.2.5.3.2. Market
Forecast, 2021 – 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2020
9.2.2.5.4.2. Market
Forecast, 2021 – 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 – 2020
9.2.2.5.5.2. Market
Forecast, 2021 – 2029
9.2.3. Autoimmune
Diseases
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 – 2020
9.2.3.3. Market Forecast, 2021 – 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 – 2020
9.2.3.5.1.2. Market
Forecast, 2021 – 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2020
9.2.3.5.2.2. Market
Forecast, 2021 – 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2020
9.2.3.5.3.2. Market
Forecast, 2021 – 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2020
9.2.3.5.4.2. Market
Forecast, 2021 – 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 – 2020
9.2.3.5.5.2. Market
Forecast, 2021 – 2029
9.2.4. Neurodegenerative
Diseases
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 – 2020
9.2.4.3. Market Forecast, 2021 – 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 – 2020
9.2.4.5.1.2. Market
Forecast, 2021 – 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2020
9.2.4.5.2.2. Market
Forecast, 2021 – 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2020
9.2.4.5.3.2. Market
Forecast, 2021 – 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2020
9.2.4.5.4.2. Market
Forecast, 2021 – 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 – 2020
9.2.4.5.5.2. Market
Forecast, 2021 – 2029
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 – 2020
9.2.5.3. Market Forecast, 2021 – 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 – 2020
9.2.5.5.1.2. Market
Forecast, 2021 – 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2020
9.2.5.5.2.2. Market
Forecast, 2021 – 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2020
9.2.5.5.3.2. Market
Forecast, 2021 – 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2020
9.2.5.5.4.2. Market
Forecast, 2021 – 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 – 2020
9.2.5.5.5.2. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapeutic Indication
10. Global Natural Killer Cells Therapeutics Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Source
10.2.1. Peripheral
Blood
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2020
10.2.1.3. Market Forecast, 2021 – 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 – 2020
10.2.1.5.1.2. Market
Forecast, 2021 – 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2020
10.2.1.5.2.2. Market
Forecast, 2021 – 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2020
10.2.1.5.3.2. Market
Forecast, 2021 – 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2020
10.2.1.5.4.2. Market
Forecast, 2021 – 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 – 2020
10.2.1.5.5.2. Market
Forecast, 2021 – 2029
10.2.2. Umbilical
Cord Blood
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2020
10.2.2.3. Market Forecast, 2021 – 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 – 2020
10.2.2.5.1.2. Market
Forecast, 2021 – 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2020
10.2.2.5.2.2. Market
Forecast, 2021 – 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2020
10.2.2.5.3.2. Market
Forecast, 2021 – 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2020
10.2.2.5.4.2. Market
Forecast, 2021 – 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 – 2020
10.2.2.5.5.2. Market
Forecast, 2021 – 2029
10.2.3. Induced
Pluripotent Stem Cell (iPSC)
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 – 2020
10.2.3.3. Market Forecast, 2021 – 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 – 2020
10.2.3.5.1.2. Market
Forecast, 2021 – 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2020
10.2.3.5.2.2. Market
Forecast, 2021 – 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2020
10.2.3.5.3.2. Market
Forecast, 2021 – 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2020
10.2.3.5.4.2. Market
Forecast, 2021 – 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 – 2020
10.2.3.5.5.2. Market
Forecast, 2021 – 2029
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 – 2020
10.2.4.3. Market Forecast, 2021 – 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 – 2020
10.2.4.5.1.2. Market
Forecast, 2021 – 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2020
10.2.4.5.2.2. Market
Forecast, 2021 – 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2020
10.2.4.5.3.2. Market
Forecast, 2021 – 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2020
10.2.4.5.4.2. Market
Forecast, 2021 – 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 – 2020
10.2.4.5.5.2. Market
Forecast, 2021 – 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Source
11. Global Natural Killer Cells Therapeutics Market Analysis and
Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
11.2.1. Hospitals
and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2020
11.2.1.3. Market Forecast, 2021 – 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 – 2020
11.2.1.5.1.2. Market
Forecast, 2021 – 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2020
11.2.1.5.2.2. Market
Forecast, 2021 – 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2020
11.2.1.5.3.2. Market
Forecast, 2021 – 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2020
11.2.1.5.4.2. Market
Forecast, 2021 – 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 – 2020
11.2.1.5.5.2. Market
Forecast, 2021 – 2029
11.2.2. Research
Institutes
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 – 2020
11.2.2.3. Market Forecast, 2021 – 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 – 2020
11.2.2.5.1.2. Market
Forecast, 2021 – 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2020
11.2.2.5.2.2. Market
Forecast, 2021 – 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2020
11.2.2.5.3.2. Market
Forecast, 2021 – 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2020
11.2.2.5.4.2. Market
Forecast, 2021 – 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 – 2020
11.2.2.5.5.2. Market
Forecast, 2021 – 2029
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 – 2020
11.2.3.3. Market Forecast, 2021 – 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 – 2020
11.2.3.5.1.2. Market
Forecast, 2021 – 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2020
11.2.3.5.2.2. Market
Forecast, 2021 – 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2020
11.2.3.5.3.2. Market
Forecast, 2021 – 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2020
11.2.3.5.4.2. Market
Forecast, 2021 – 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 – 2020
11.2.3.5.5.2. Market
Forecast, 2021 – 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Users
12. North America Natural Killer Cells Therapeutics Market
Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. North
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
12.2. North
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Type
12.2.1. NK Cell
Therapies
12.2.2. Antibody
Directed NK Cell Therapies
12.3. North
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
12.3.1. Cancer
12.3.2. Viral
Infections
12.3.3. Autoimmune
Diseases
12.3.4. Neurodegenerative
Diseases
12.3.5. Others
12.4. North
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Source
12.4.1. Peripheral
Blood
12.4.2. Umbilical
Cord Blood
12.4.3. Induced
Pluripotent Stem Cell (iPSC)
12.4.4. Others
12.5. North
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.1. Hospitals
and Clinics
12.5.2. Research
Institutes
12.5.3. Others
12.6. North
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Country
12.6.1. U.S
12.6.1.1. U.S Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Type
12.6.1.1.1. NK Cell Therapies
12.6.1.1.2. Antibody Directed NK Cell Therapies
12.6.1.2. U.S Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
12.6.1.2.1. Cancer
12.6.1.2.2. Viral Infections
12.6.1.2.3. Autoimmune Diseases
12.6.1.2.4. Neurodegenerative Diseases
12.6.1.2.5. Others
12.6.1.3. U.S Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Source
12.6.1.3.1. Peripheral Blood
12.6.1.3.2. Umbilical Cord Blood
12.6.1.3.3. Induced Pluripotent Stem Cell (iPSC)
12.6.1.3.4. Others
12.6.1.4. U.S Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By End Users
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Research Institutes
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
12.6.2.1.1. NK Cell Therapies
12.6.2.1.2. Antibody Directed NK Cell Therapies
12.6.2.2. Canada Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
12.6.2.2.1. Cancer
12.6.2.2.2. Viral Infections
12.6.2.2.3. Autoimmune Diseases
12.6.2.2.4. Neurodegenerative Diseases
12.6.2.2.5. Others
12.6.2.3. Canada Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
12.6.2.3.1. Peripheral Blood
12.6.2.3.2. Umbilical Cord Blood
12.6.2.3.3. Induced Pluripotent Stem Cell (iPSC)
12.6.2.3.4. Others
12.6.2.4. Canada Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Research Institutes
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
12.6.3.1.1. NK Cell Therapies
12.6.3.1.2. Antibody Directed NK Cell Therapies
12.6.3.2. Mexico Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
12.6.3.2.1. Cancer
12.6.3.2.2. Viral Infections
12.6.3.2.3. Autoimmune Diseases
12.6.3.2.4. Neurodegenerative Diseases
12.6.3.2.5. Others
12.6.3.3. Mexico Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
12.6.3.3.1. Peripheral Blood
12.6.3.3.2. Umbilical Cord Blood
12.6.3.3.3. Induced Pluripotent Stem Cell (iPSC)
12.6.3.3.4. Others
12.6.3.4. Mexico Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Research Institutes
12.6.3.4.3. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Type
12.6.4.1.1. NK Cell Therapies
12.6.4.1.2. Antibody Directed NK Cell Therapies
12.6.4.2. Rest of North America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.6.4.2.1. Cancer
12.6.4.2.2. Viral Infections
12.6.4.2.3. Autoimmune Diseases
12.6.4.2.4. Neurodegenerative Diseases
12.6.4.2.5. Others
12.6.4.3. Rest of North America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Source
12.6.4.3.1. Peripheral Blood
12.6.4.3.2. Umbilical Cord Blood
12.6.4.3.3. Induced Pluripotent Stem Cell (iPSC)
12.6.4.3.4. Others
12.6.4.4. Rest of North America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Research Institutes
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By Type
12.7.3. By
Therapeutic Indication
12.7.4. By
Source
12.7.5. By End
Users
13. Europe Natural Killer Cells Therapeutics Market Analysis and
Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Europe
Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
13.2. Europe
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Type
13.2.1. NK Cell
Therapies
13.2.2. Antibody
Directed NK Cell Therapies
13.3. Europe
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.3.1. Cancer
13.3.2. Viral
Infections
13.3.3. Autoimmune
Diseases
13.3.4. Neurodegenerative
Diseases
13.3.5. Others
13.4. Europe
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Source
13.4.1. Peripheral
Blood
13.4.2. Umbilical
Cord Blood
13.4.3. Induced
Pluripotent Stem Cell (iPSC)
13.4.4. Others
13.5. Europe
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.1. Hospitals
and Clinics
13.5.2. Research
Institutes
13.5.3. Others
13.6. Europe
Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.1. France
13.6.1.1. France Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
13.6.1.1.1. NK Cell Therapies
13.6.1.1.2. Antibody Directed NK Cell Therapies
13.6.1.2. France Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
13.6.1.2.1. Cancer
13.6.1.2.2. Viral Infections
13.6.1.2.3. Autoimmune Diseases
13.6.1.2.4. Neurodegenerative Diseases
13.6.1.2.5. Others
13.6.1.3. France Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
13.6.1.3.1. Peripheral Blood
13.6.1.3.2. Umbilical Cord Blood
13.6.1.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.1.3.4. Others
13.6.1.4. France Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Research Institutes
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
13.6.2.1.1. NK Cell Therapies
13.6.2.1.2. Antibody Directed NK Cell Therapies
13.6.2.2. The UK Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
13.6.2.2.1. Cancer
13.6.2.2.2. Viral Infections
13.6.2.2.3. Autoimmune Diseases
13.6.2.2.4. Neurodegenerative Diseases
13.6.2.2.5. Others
13.6.2.3. The UK Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
13.6.2.3.1. Peripheral Blood
13.6.2.3.2. Umbilical Cord Blood
13.6.2.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.2.3.4. Others
13.6.2.4. The UK Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Research Institutes
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
13.6.3.1.1. NK Cell Therapies
13.6.3.1.2. Antibody Directed NK Cell Therapies
13.6.3.2. Spain Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
13.6.3.2.1. Cancer
13.6.3.2.2. Viral Infections
13.6.3.2.3. Autoimmune Diseases
13.6.3.2.4. Neurodegenerative Diseases
13.6.3.2.5. Others
13.6.3.3. Spain Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
13.6.3.3.1. Peripheral Blood
13.6.3.3.2. Umbilical Cord Blood
13.6.3.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.3.3.4. Others
13.6.3.4. Spain Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Research Institutes
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
13.6.4.1.1. NK Cell Therapies
13.6.4.1.2. Antibody Directed NK Cell Therapies
13.6.4.2. Germany Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
13.6.4.2.1. Cancer
13.6.4.2.2. Viral Infections
13.6.4.2.3. Autoimmune Diseases
13.6.4.2.4. Neurodegenerative Diseases
13.6.4.2.5. Others
13.6.4.3. Germany Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
13.6.4.3.1. Peripheral Blood
13.6.4.3.2. Umbilical Cord Blood
13.6.4.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.4.3.4. Others
13.6.4.4. Germany Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Research Institutes
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
13.6.5.1.1. NK Cell Therapies
13.6.5.1.2. Antibody Directed NK Cell Therapies
13.6.5.2. Italy Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
13.6.5.2.1. Cancer
13.6.5.2.2. Viral Infections
13.6.5.2.3. Autoimmune Diseases
13.6.5.2.4. Neurodegenerative Diseases
13.6.5.2.5. Others
13.6.5.3. Italy Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
13.6.5.3.1. Peripheral Blood
13.6.5.3.2. Umbilical Cord Blood
13.6.5.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.5.3.4. Others
13.6.5.4. Italy Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Research Institutes
13.6.5.4.3. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Type
13.6.6.1.1. NK Cell Therapies
13.6.6.1.2. Antibody Directed NK Cell Therapies
13.6.6.2. Nordic Countries Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.6.6.2.1. Cancer
13.6.6.2.2. Viral Infections
13.6.6.2.3. Autoimmune Diseases
13.6.6.2.4. Neurodegenerative Diseases
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Source
13.6.6.3.1. Peripheral Blood
13.6.6.3.2. Umbilical Cord Blood
13.6.6.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.6.3.4. Others
13.6.6.4. Nordic Countries Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Research Institutes
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
13.6.7.1.1. NK Cell Therapies
13.6.7.1.2. Antibody Directed NK Cell Therapies
13.6.7.2. Benelux Union Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
13.6.7.2.1. Cancer
13.6.7.2.2. Viral Infections
13.6.7.2.3. Autoimmune Diseases
13.6.7.2.4. Neurodegenerative Diseases
13.6.7.2.5. Others
13.6.7.3. Benelux Union Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
13.6.7.3.1. Peripheral Blood
13.6.7.3.2. Umbilical Cord Blood
13.6.7.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.7.3.4. Others
13.6.7.4. Benelux Union Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Research Institutes
13.6.7.4.3. Others
13.6.7.5. Benelux Union Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Type
13.6.8.1.1. NK Cell Therapies
13.6.8.1.2. Antibody Directed NK Cell Therapies
13.6.8.2. Rest of Europe Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.6.8.2.1. Cancer
13.6.8.2.2. Viral Infections
13.6.8.2.3. Autoimmune Diseases
13.6.8.2.4. Neurodegenerative Diseases
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Source
13.6.8.3.1. Peripheral Blood
13.6.8.3.2. Umbilical Cord Blood
13.6.8.3.3. Induced Pluripotent Stem Cell (iPSC)
13.6.8.3.4. Others
13.6.8.4. Rest of Europe Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Research Institutes
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By Type
13.7.3. By
Therapeutic Indication
13.7.4. By
Source
13.7.5. By End
Users
14. Asia Pacific Natural Killer Cells Therapeutics Market
Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Asia
Pacific Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
14.2. Asia
Pacific Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Type
14.2.1. NK Cell
Therapies
14.2.2. Antibody
Directed NK Cell Therapies
14.3. Asia
Pacific Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.3.1. Cancer
14.3.2. Viral
Infections
14.3.3. Autoimmune
Diseases
14.3.4. Neurodegenerative
Diseases
14.3.5. Others
14.4. Asia
Pacific Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Source
14.4.1. Peripheral
Blood
14.4.2. Umbilical
Cord Blood
14.4.3. Induced
Pluripotent Stem Cell (iPSC)
14.4.4. Others
14.5. Asia
Pacific Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.1. Hospitals
and Clinics
14.5.2. Research
Institutes
14.5.3. Others
14.6. Asia
Pacific Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.1. China
14.6.1.1. China Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
14.6.1.1.1. NK Cell Therapies
14.6.1.1.2. Antibody Directed NK Cell Therapies
14.6.1.2. China Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
14.6.1.2.1. Cancer
14.6.1.2.2. Viral Infections
14.6.1.2.3. Autoimmune Diseases
14.6.1.2.4. Neurodegenerative Diseases
14.6.1.2.5. Others
14.6.1.3. China Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
14.6.1.3.1. Peripheral Blood
14.6.1.3.2. Umbilical Cord Blood
14.6.1.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.1.3.4. Others
14.6.1.4. China Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Research Institutes
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
14.6.2.1.1. NK Cell Therapies
14.6.2.1.2. Antibody Directed NK Cell Therapies
14.6.2.2. Japan Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
14.6.2.2.1. Cancer
14.6.2.2.2. Viral Infections
14.6.2.2.3. Autoimmune Diseases
14.6.2.2.4. Neurodegenerative Diseases
14.6.2.2.5. Others
14.6.2.3. Japan Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
14.6.2.3.1. Peripheral Blood
14.6.2.3.2. Umbilical Cord Blood
14.6.2.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.2.3.4. Others
14.6.2.4. Japan Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Research Institutes
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
14.6.3.1.1. NK Cell Therapies
14.6.3.1.2. Antibody Directed NK Cell Therapies
14.6.3.2. India Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
14.6.3.2.1. Cancer
14.6.3.2.2. Viral Infections
14.6.3.2.3. Autoimmune Diseases
14.6.3.2.4. Neurodegenerative Diseases
14.6.3.2.5. Others
14.6.3.3. India Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
14.6.3.3.1. Peripheral Blood
14.6.3.3.2. Umbilical Cord Blood
14.6.3.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.3.3.4. Others
14.6.3.4. India Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Research Institutes
14.6.3.4.3. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.4.1.1. NK Cell Therapies
14.6.4.1.2. Antibody Directed NK Cell Therapies
14.6.4.2. New Zealand Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.6.4.2.1. Cancer
14.6.4.2.2. Viral Infections
14.6.4.2.3. Autoimmune Diseases
14.6.4.2.4. Neurodegenerative Diseases
14.6.4.2.5. Others
14.6.4.3. New Zealand Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
14.6.4.3.1. Peripheral Blood
14.6.4.3.2. Umbilical Cord Blood
14.6.4.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.4.3.4. Others
14.6.4.4. New Zealand Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Research Institutes
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.5.1.1. NK Cell Therapies
14.6.5.1.2. Antibody Directed NK Cell Therapies
14.6.5.2. Australia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.6.5.2.1. Cancer
14.6.5.2.2. Viral Infections
14.6.5.2.3. Autoimmune Diseases
14.6.5.2.4. Neurodegenerative Diseases
14.6.5.2.5. Others
14.6.5.3. Australia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
14.6.5.3.1. Peripheral Blood
14.6.5.3.2. Umbilical Cord Blood
14.6.5.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.5.3.4. Others
14.6.5.4. Australia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Research Institutes
14.6.5.4.3. Others
14.6.6. South
Korea
14.6.6.1. South Korea Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.6.1.1. NK Cell Therapies
14.6.6.1.2. Antibody Directed NK Cell Therapies
14.6.6.2. South Korea Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.6.6.2.1. Cancer
14.6.6.2.2. Viral Infections
14.6.6.2.3. Autoimmune Diseases
14.6.6.2.4. Neurodegenerative Diseases
14.6.6.2.5. Others
14.6.6.3. South Korea Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
14.6.6.3.1. Peripheral Blood
14.6.6.3.2. Umbilical Cord Blood
14.6.6.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.6.3.4. Others
14.6.6.4. South Korea Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Research Institutes
14.6.6.4.3. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Type
14.6.7.1.1. NK Cell Therapies
14.6.7.1.2. Antibody Directed NK Cell Therapies
14.6.7.2. Southeast Asia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.6.7.2.1. Cancer
14.6.7.2.2. Viral Infections
14.6.7.2.3. Autoimmune Diseases
14.6.7.2.4. Neurodegenerative Diseases
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Source
14.6.7.3.1. Peripheral Blood
14.6.7.3.2. Umbilical Cord Blood
14.6.7.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.7.3.4. Others
14.6.7.4. Southeast Asia Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Research Institutes
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Type
14.6.8.1.1. NK Cell Therapies
14.6.8.1.2. Antibody Directed NK Cell Therapies
14.6.8.2. Rest of Asia Pacific Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.6.8.2.1. Cancer
14.6.8.2.2. Viral Infections
14.6.8.2.3. Autoimmune Diseases
14.6.8.2.4. Neurodegenerative Diseases
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Source
14.6.8.3.1. Peripheral Blood
14.6.8.3.2. Umbilical Cord Blood
14.6.8.3.3. Induced Pluripotent Stem Cell (iPSC)
14.6.8.3.4. Others
14.6.8.4. Rest of Asia Pacific Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Research Institutes
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By Type
14.7.3. By
Therapeutic Indication
14.7.4. By
Source
14.7.5. By End
Users
15. Middle East and Africa Natural Killer Cells Therapeutics
Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Middle
East and Africa Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
15.2. Middle
East and Africa Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Type
15.2.1. NK Cell
Therapies
15.2.2. Antibody
Directed NK Cell Therapies
15.3. Middle
East and Africa Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.3.1. Cancer
15.3.2. Viral
Infections
15.3.3. Autoimmune
Diseases
15.3.4. Neurodegenerative
Diseases
15.3.5. Others
15.4. Middle
East and Africa Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Source
15.4.1. Peripheral
Blood
15.4.2. Umbilical
Cord Blood
15.4.3. Induced
Pluripotent Stem Cell (iPSC)
15.4.4. Others
15.5. Middle
East and Africa Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.1. Hospitals
and Clinics
15.5.2. Research
Institutes
15.5.3. Others
15.6. Middle
East and Africa Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
15.6.1.1.1. NK Cell Therapies
15.6.1.1.2. Antibody Directed NK Cell Therapies
15.6.1.2. Saudi Arabia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
15.6.1.2.1. Cancer
15.6.1.2.2. Viral Infections
15.6.1.2.3. Autoimmune Diseases
15.6.1.2.4. Neurodegenerative Diseases
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
15.6.1.3.1. Peripheral Blood
15.6.1.3.2. Umbilical Cord Blood
15.6.1.3.3. Induced Pluripotent Stem Cell (iPSC)
15.6.1.3.4. Others
15.6.1.4. Saudi Arabia Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Research Institutes
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Type
15.6.2.1.1. NK Cell Therapies
15.6.2.1.2. Antibody Directed NK Cell Therapies
15.6.2.2. UAE Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
15.6.2.2.1. Cancer
15.6.2.2.2. Viral Infections
15.6.2.2.3. Autoimmune Diseases
15.6.2.2.4. Neurodegenerative Diseases
15.6.2.2.5. Others
15.6.2.3. UAE Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Source
15.6.2.3.1. Peripheral Blood
15.6.2.3.2. Umbilical Cord Blood
15.6.2.3.3. Induced Pluripotent Stem Cell (iPSC)
15.6.2.3.4. Others
15.6.2.4. UAE Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Research Institutes
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
15.6.3.1.1. NK Cell Therapies
15.6.3.1.2. Antibody Directed NK Cell Therapies
15.6.3.2. Egypt Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
15.6.3.2.1. Cancer
15.6.3.2.2. Viral Infections
15.6.3.2.3. Autoimmune Diseases
15.6.3.2.4. Neurodegenerative Diseases
15.6.3.2.5. Others
15.6.3.3. Egypt Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
15.6.3.3.1. Peripheral Blood
15.6.3.3.2. Umbilical Cord Blood
15.6.3.3.3. Induced Pluripotent Stem Cell (iPSC)
15.6.3.3.4. Others
15.6.3.4. Egypt Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Research Institutes
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
15.6.4.1.1. NK Cell Therapies
15.6.4.1.2. Antibody Directed NK Cell Therapies
15.6.4.2. Kuwait Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
15.6.4.2.1. Cancer
15.6.4.2.2. Viral Infections
15.6.4.2.3. Autoimmune Diseases
15.6.4.2.4. Neurodegenerative Diseases
15.6.4.2.5. Others
15.6.4.3. Kuwait Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
15.6.4.3.1. Peripheral Blood
15.6.4.3.2. Umbilical Cord Blood
15.6.4.3.3. Induced Pluripotent Stem Cell (iPSC)
15.6.4.3.4. Others
15.6.4.4. Kuwait Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Research Institutes
15.6.4.4.3. Others
15.6.5. South
Africa
15.6.5.1. South Africa Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
15.6.5.1.1. NK Cell Therapies
15.6.5.1.2. Antibody Directed NK Cell Therapies
15.6.5.2. South Africa Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
15.6.5.2.1. Cancer
15.6.5.2.2. Viral Infections
15.6.5.2.3. Autoimmune Diseases
15.6.5.2.4. Neurodegenerative Diseases
15.6.5.2.5. Others
15.6.5.3. South Africa Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
15.6.5.3.1. Peripheral Blood
15.6.5.3.2. Umbilical Cord Blood
15.6.5.3.3. Induced Pluripotent Stem Cell (iPSC)
15.6.5.3.4. Others
15.6.5.4. South Africa Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Research Institutes
15.6.5.4.3. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Natural Killer Cells
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Type
15.6.6.1.1. NK Cell Therapies
15.6.6.1.2. Antibody Directed NK Cell Therapies
15.6.6.2. Rest of Middle East & Africa Natural Killer Cells
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.6.6.2.1. Cancer
15.6.6.2.2. Viral Infections
15.6.6.2.3. Autoimmune Diseases
15.6.6.2.4. Neurodegenerative Diseases
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Natural Killer Cells
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Source
15.6.6.3.1. Peripheral Blood
15.6.6.3.2. Umbilical Cord Blood
15.6.6.3.3. Induced Pluripotent Stem Cell (iPSC)
15.6.6.3.4. Others
15.6.6.4. Rest of Middle East & Africa Natural Killer Cells
Therapeutics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Research Institutes
15.6.6.4.3. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Type
15.7.3. By
Therapeutic Indication
15.7.4. By
Source
15.7.5. By End
Users
16. Latin America Natural Killer Cells Therapeutics Market
Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Latin
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn)
16.2. Latin
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Type
16.2.1. NK Cell
Therapies
16.2.2. Antibody
Directed NK Cell Therapies
16.3. Latin
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
16.3.1. Cancer
16.3.2. Viral
Infections
16.3.3. Autoimmune
Diseases
16.3.4. Neurodegenerative
Diseases
16.3.5. Others
16.4. Latin
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Source
16.4.1. Peripheral
Blood
16.4.2. Umbilical
Cord Blood
16.4.3. Induced
Pluripotent Stem Cell (iPSC)
16.4.4. Others
16.5. Latin
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
16.5.1. Hospitals
and Clinics
16.5.2. Research
Institutes
16.5.3. Others
16.6. Latin
America Natural Killer Cells Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Type
16.6.1.1.1. NK Cell Therapies
16.6.1.1.2. Antibody Directed NK Cell Therapies
16.6.1.2. Brazil Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
16.6.1.2.1. Cancer
16.6.1.2.2. Viral Infections
16.6.1.2.3. Autoimmune Diseases
16.6.1.2.4. Neurodegenerative Diseases
16.6.1.2.5. Others
16.6.1.3. Brazil Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By Source
16.6.1.3.1. Peripheral Blood
16.6.1.3.2. Umbilical Cord Blood
16.6.1.3.3. Induced Pluripotent Stem Cell (iPSC)
16.6.1.3.4. Others
16.6.1.4. Brazil Natural Killer Cells Therapeutics Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Research Institutes
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Type
16.6.2.1.1. NK Cell Therapies
16.6.2.1.2. Antibody Directed NK Cell Therapies
16.6.2.2. Argentina Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
16.6.2.2.1. Cancer
16.6.2.2.2. Viral Infections
16.6.2.2.3. Autoimmune Diseases
16.6.2.2.4. Neurodegenerative Diseases
16.6.2.2.5. Others
16.6.2.3. Argentina Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Source
16.6.2.3.1. Peripheral Blood
16.6.2.3.2. Umbilical Cord Blood
16.6.2.3.3. Induced Pluripotent Stem Cell (iPSC)
16.6.2.3.4. Others
16.6.2.4. Argentina Natural Killer Cells Therapeutics Market Revenue
(US$ Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Research Institutes
16.6.2.4.3. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Type
16.6.3.1.1. NK Cell Therapies
16.6.3.1.2. Antibody Directed NK Cell Therapies
16.6.3.2. Rest of Latin America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
16.6.3.2.1. Cancer
16.6.3.2.2. Viral Infections
16.6.3.2.3. Autoimmune Diseases
16.6.3.2.4. Neurodegenerative Diseases
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Source
16.6.3.3.1. Peripheral Blood
16.6.3.3.2. Umbilical Cord Blood
16.6.3.3.3. Induced Pluripotent Stem Cell (iPSC)
16.6.3.3.4. Others
16.6.3.4. Rest of Latin America Natural Killer Cells Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Research Institutes
16.6.3.4.3. Others
16.7. Key Segment
for Channeling Investments
16.7.1. By
Country
16.7.2. By Type
16.7.3. By
Therapeutic Indication
16.7.4. By
Source
16.7.5. By End
Users
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2019
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Acepodia
Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Affimed
GmbH
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business Strategies
18.3. Artiva Biotherapeutics, Inc.
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Bellicum Phamaceuticals, Inc.
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Cytovia Therapeutics
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Dragonfly Therapeutics
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. EMERCell
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT Analysis
18.7.7. Business
Strategies
18.8. Fate Therapeutics
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Fortress Biotech, Inc.
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Glycostem
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. ImmunityBio, Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Innate Pharma S.A.
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Kiadis Pharma
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Nkarta, Inc.
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business
Strategies
18.15. NKGen Biotech
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. NKMAX Co., Ltd.
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business
Strategies
18.17. ONK Therapeutics Limited
18.17.1. Company
Details
18.17.2. Company
Overview
18.17.3. Product
Offerings
18.17.4. Key
Developments
18.17.5. Financial
Analysis
18.17.6. SWOT
Analysis
18.17.7. Business Strategies
18.18. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
